Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: An analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

European Heart Journal

Volumn 31, Issue 1, 2010, Pages 92-99

  Burgess, David C ^a   Hunt, David ^b   Li, Liping ^a   Zannino, Diana ^a   Williamson, Elizabeth ^a   Davis, Timothy M E ^c   Laakso, Markku ^d   Kesäniemi, Y Antero ^e   Zhang, Jun ^a   Sy, Raymond W ^a   Lehto, Seppo ^d   Mann, Stewart ^f   Keech, Anthony C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

Fenofibrate; Silent myocardial infarction; Type 2 diabetes

Indexed keywords

CHOLESTEROL; FENOFIBRATE; INSULIN; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SILENT MYOCARDIAL INFARCTION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ELECTROCARDIOGRAPHY; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 73949113394     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp377     Document Type: Article

References (34)

1. Sheifer SE, Manollo TA, Gersh BJ. Unrecognized myocardial infarction. Ann Intern Med 2001;135:801-811.
2. Airaksinen KE. Silent coronary artery disease in diabetes\-a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia 2001;44:259-266.
3. Davis TM, Fortun P, Mulder J, Davis WA, Bruce DG, Fremantle Diabetes Study. Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: the Fremantle Diabetes Study. Diabetologia 2004;47: 395-399.
4. Valensi P, Paries J, Brulport-Cerisier V, Torremocha F, Sachs R, Vanzetto G, Cosson E, Lormeau B, Attali J, Marechaud R, Estour B, Halimi S. Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study. Diabetes Care 2005;28:2722-2727.
5. Sejil S, Janand-Delenne B, Avierinos J, Habib G, Labastie N, Raccah D, Vague P, Lassmann-Vague V. Six-year follow-up of a cohort of 203 patients with diabetes after screening for silent myocardial ischaemia. Diabet Med 2006;23: 1186-1191.
6. Aguilar D, Goldhaber SZ, Gans DJ, Levey AS, Porush JG, Lewis JB, Rouleau J, Berl T, Lewis EJ, Pfeffer MA, Collaborative Study Group. Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. Am J Cardiol 2004;94:337-339.
7. Araz M, Celen Z, Akdemir I, Okan V. Frequency of silent myocardial ischemia in type 2 diabetic patients and the relation with poor glycemic control. Acta Diabetol 2004;41:38-43.
8. Fornengo P, Bosio A, Epifani G, Pallisco O, Mancuso A, Pascale C. Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. Diabetic Med 2006;23:775-779.
9. Gokcel A, Aydin M, Yalcin F, Yapar AF, Ertorer ME, Ozsahin AK, Muderrisoglu H, Aktas A, Guvener N, Akbaba M. Silent coronary artery disease in patients with type 2 diabetes mellitus. Acta Diabetol 2003;40:176-180. (Pubitemid 37548150)
10. Kannel WB. Prevalence and clinical aspects of unrecognized myocardial infarction and sudden unexpected death. Circulation 1987;75:II4-II5.
11. May O, Arildsen H, Damsgaard E, Mickley H. Prevalence and prediction of silent ischaemia in diabetes mellitus: a population-based study. Cardiovasc Res 1997;34: 241-247.
12. Moller CS, Byberg L, Sundstrom J, Lind L. T wave abnormalities, high body mass index, current smoking and high lipoprotein (a) levels predict the development of major abnormal Q/QS patterns 20 years later. A population-based study. BMC Cardiovasc Disord 2006;6:10.
13. Naka M, Hiramatsu K, Aizawa T, Momose A, Yoshizawa K, Shigematsu S, Ishihara F, Niwa A, Yamada T. Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart J 1992;123:46-53.
14. Rosenman RH, Friedman M, Jenkins CD, Strus R, Wurm M, Kositchek R. Clinically Unrecognised Myocardial Infarction in the Western Collaborative Group Study. Am J Cardiol 1967;19:771-775.
15. Tarkun I, Cetinarslan B, Canturk Z, Tarkun P, Agacdiken A, Komsuoglu B. Homo-cysteine concentrations in type 2 diabetic patients with silent myocardial ischemia A predictive marker. J Diabetes Complicat 2004;18:165-168.
16. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861.
17. Blackburn H, Keys A, Simonson E, Rautaharju PM, Punsar S. The electrocardiogram in population studies. A classification system. Circulation 1960;21: 1160-1175.
18. Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Chichester: Wiley; 1995.
19. Hosmer D, Lemonshow S. Applied Survival Analysis Regression Modelling of Time to Event Data. New York: Wiley; 1999.
20. Rothman KJ. No adjustments are needed for multiple testing. Epidemiology 1990;1: 43-46.
21. Earle KA, Mishra M, Morocutti A, Barnes D, Stephens E, Chambers J, Viberti GC. Microalbuminuria as a marker for silent myocardial ischemia in IDDM patients. Diabetologia 1996;39:854-856.
22. Rutter MK, McComb JM, Brady S, Marshall SM. Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus. Am J Cardiol 1999;83:27-31.
23. Chico A, Tomas A, Novials A. Silent myocardial ischemia is associated with autonomic neuropathy and other cardiovascular risk factors in type 1 and type 2 diabetic subjects, especially in those with microalbuminuria. Endocrine 2005; 27:213-217.
24. Rutter MK, Wahid ST, McComb JM, Marshall SM. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 2002;40:56-61.
25. Doubell AF. Managing the asymptomatic diabetic patient with silent myocardial ischaemia. Cardiovasc J S Afr 2002;13:189-193.
26. Bacci S, Villella M, Villella A, Langialonga T, Grilli M, Rauseo A, Mastroianno S, De Cosmo S, Fanelli R, Trischitta V. Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur J Endocrinol 2002;147:649-654.
27. Koek HL, Soedamah-Muthu SS, Kardaun JWPF, Gevers E, de Bruin A, Reitsma JB, Bots ML, Grobbee DE. Short-and long-term mortality after acute myocardial infarction: comparison of pateints with and without diabetes mellitus. Eur J Epidemiol 2007;22:883-888.
28. Norhammar A, Lindbäch J, Rydén L, Wallentin L, Stenestrand U, on behalf of the Register of Information Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Improved but still high short-and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 2007;93:1577-1583.
29. Wilson SR, Sanborn TA, Vakili BA, Brown DL, Sherman W. Effect of diabetes on long-term mortality following contemporary percutaneous coronary intervention. Diabetes Care 2004;27:1137-1142.
30. Leavitt BJ, Sheppard L, Maloney C, Clough RA, Braxton JH, Charlesworth DC, Weintraub RM, Hernandez F, Olmstrad EM, Nugent WC, O'Connor GT, Ross CS, and for the Northern New England Cardiovascular Disease Study Group. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation 2004;110:II-41-II-44. (Pubitemid 39263696)
31. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979;44:53-59.
32. Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Unrecognized myocar-dial infarction: epidemiology, clinical characteristics, and the prognostic role of angina pectoris: the Reykjavik Study. Ann Intern Med 1995;122:96-102.
33. Marcus EB, Yano K, MacLean CJ. Regression of Q waves following acute myocar-dial infarction. Am J Epidemiol 1989;129:105-111.
34. Sztajzel J, Urban P. Early and late Q wave regression in the setting of acute myo-cardial infarction. Heart 2000;83:708-710.